Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01987362
- Locations
- 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 230
- Registration Number
- NCT01987492
- Locations
- 🇧🇪
Clin Univ de Bxl Hôpital Erasme, Bruxelles, Belgium
🇦🇺Monash Medical Centre; Respiratory and Sleep Medicine, Clayton, Victoria, Australia
🇧🇪Longartsenpraktijk, Genk, Belgium
A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT01987479
- Locations
- 🇳🇱
Gelre Ziekenhuizen; Reumatologie, Apeldoorn, Netherlands
🇳🇱Antonius Ziekenhuis Sneek; Department of Rheumatology, Sneek, Netherlands
🇳🇱Amphia ziekenhuis, locatie langendijk, Breda, Netherlands
A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT01984229
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 305
- Registration Number
- NCT01984242
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of California, San Francisco, California, United States
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
- Conditions
- Polycythemia VeraPrimary MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
- Interventions
- Biological: RO7490677
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 125
- Registration Number
- NCT01981850
- Locations
- 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01981005
An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)
- Conditions
- Anemia
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 661
- Registration Number
- NCT01974271
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01974258
A Study of the Effect of Multiple Doses of Itraconazole and Fluoxetine on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT01967979